161 related articles for article (PubMed ID: 22413715)
1. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715
[TBL] [Abstract][Full Text] [Related]
2. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
Vaughan Sarrazin MS; Jones M; Mazur A; Chrischilles E; Cram P
Am J Med; 2014 Dec; 127(12):1179-85. PubMed ID: 25107386
[TBL] [Abstract][Full Text] [Related]
3. Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.
Alonso A; Bengtson LG; MacLehose RF; Lutsey PL; Chen LY; Lakshminarayan K
Stroke; 2014 Aug; 45(8):2286-91. PubMed ID: 24994722
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.
Carles M; Brosa M; Souto JC; Garcia-Alamino JM; Guyatt G; Alonso-Coello P
BMC Health Serv Res; 2015 Jul; 15():289. PubMed ID: 26215871
[TBL] [Abstract][Full Text] [Related]
5. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
Alikhan R; Rayment R; Keeling D; Baglin T; Benson G; Green L; Marshall S; Patel R; Pavord S; Rose P; Tait C
Emerg Med J; 2014 Feb; 31(2):163-8. PubMed ID: 23435652
[TBL] [Abstract][Full Text] [Related]
6. LOWERING THE RISK FOR THROMBUS AND STROKE IN ATRIAL FIBRILLATION PATIENTS: Will Dabigatran Replace Warfarin?
Tan AY; Rosenberg MA
Clin Med Rev Vasc Health; 2013 Jun; 5():1-8. PubMed ID: 25253992
[TBL] [Abstract][Full Text] [Related]
7. Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin.
Amini S; Gholami K; Bakhshandeh H; Fariborz Farsad B
Iran J Pharm Res; 2013; 12(4):945-53. PubMed ID: 24523776
[TBL] [Abstract][Full Text] [Related]
8. Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease.
Kim J; Yadava M; An IC; Sayeed A; Laird-Fick HS; Gourineni V; Abela GS
Case Rep Med; 2013; 2013():131395. PubMed ID: 24151507
[TBL] [Abstract][Full Text] [Related]
9. Pacemaker Implantation in Elderly Patients: Safety of Various Regimens of Anticoagulant Therapy.
Terekhov D; Agapov V; Kulikov K; Zadorozhnaya S; Samitin V; Maslyakov V
J Atr Fibrillation; 2017; 9(5):1467. PubMed ID: 29250265
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran excess: case report and review of the literature.
Sarma A; Rossi JE; Connors JM; Giugliano RP
Cardiol Ther; 2013 Jun; 2(1):111-24. PubMed ID: 25135294
[TBL] [Abstract][Full Text] [Related]
11. Case report: dabigatran-associated gynecologic bleeding.
Winans SA; Ademolu A
Hosp Pharm; 2013 Mar; 48(3):227-30. PubMed ID: 24421466
[TBL] [Abstract][Full Text] [Related]
12. The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio.
Safouris A; Triantafyllou N; Parissis J; Tsivgoulis G
Ther Adv Neurol Disord; 2015 Nov; 8(6):245-54. PubMed ID: 26600870
[TBL] [Abstract][Full Text] [Related]
13. Individualized anti-thrombotic therapy for acute myocardial infarction complicated with left ventricular thrombus: A case report.
Song Y; Li H; Zhang X; Wang L; Xu HY; Lu ZC; Wang XG; Liu B
World J Clin Cases; 2024 Feb; 12(4):835-841. PubMed ID: 38322693
[TBL] [Abstract][Full Text] [Related]
14. Effect of direct oral anticoagulant dabigatran on early bone healing: An experimental study in rats.
Kyriakaki I; Karanikola T; Lillis T; Kontonasaki E; Dabarakis N
J Adv Periodontol Implant Dent; 2023; 15(2):86-92. PubMed ID: 38357331
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.
Malmström RE; Godman BB; Diogene E; Baumgärtel C; Bennie M; Bishop I; Brzezinska A; Bucsics A; Campbell S; Ferrario A; Finlayson AE; Fürst J; Garuoliene K; Gomes M; Gutiérrez-Ibarluzea I; Haycox A; Hviding K; Herholz H; Hoffmann M; Jan S; Jones J; Joppi R; Kalaba M; Kvalheim C; Laius O; Langner I; Lonsdale J; Lööv SÄ; Malinowska K; McCullagh L; Paterson K; Markovic-Pekovic V; Martin A; Piessnegger J; Selke G; Sermet C; Simoens S; Tulunay C; Tomek D; Vončina L; Vlahovic-Palcevski V; Wale J; Wilcock M; Wladysiuk M; van Woerkom M; Zara C; Gustafsson LL
Front Pharmacol; 2013; 4():39. PubMed ID: 23717279
[TBL] [Abstract][Full Text] [Related]
16. Practical Suggestions for an Optimal Management of Vitamin K Antagonists: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper.
Galliazzo S; Bucciarelli P; Barcellona D; Ciampa A; Grandone E; Malcangi G; Rescigno G; Squizzato A; Toschi V; Testa S; Poli D
Thromb Haemost; 2024 Apr; ():. PubMed ID: 38626900
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran-Related Nephropathy in a Patient with Undiagnosed IgA Nephropathy.
Escoli R; Santos P; Andrade S; Carvalho F
Case Rep Nephrol; 2015; 2015():298261. PubMed ID: 26347498
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients.
Smythe MA; Forman MJ; Bertran EA; Hoffman JL; Priziola JL; Koerber JM
J Thromb Thrombolysis; 2015 Oct; 40(3):280-7. PubMed ID: 25851800
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
